Epoch HealthTrump Directs Administration to Reclassify Cannabis to Allow for Medical Research

Trump signed executive order directing cannabis reclassification from Schedule I to Schedule III to enable medical research, maintaining federal prohibition while expanding research access. The move affects millions using CBD products without medical guidance and opens Medicare/Medicaid coverage for hemp-derived products starting late 2026.

⚖️ PROFESSIONAL IMPACT

• Reclassification to Schedule III enables federally-funded research previously prohibited under Schedule I status, addressing evidence gaps physicians cite when counseling patients on cannabinoid use
• Medicare/Medicaid will cover up to $500 in hemp-derived products starting Q4 2026, requiring pharmacists and prescribers to develop guidance protocols without established clinical guidelines
• Federal prohibition remains despite reclassification, creating continued legal-clinical disconnect where physicians advise on products patients already use outside medical supervision
• Trump administration seeks legislation for “full-spectrum” CBD products with higher THC levels, potentially expanding product landscape physicians must evaluate without robust safety data

🎯 ACTION ITEMS

• Document current patient cannabinoid use during medication reconciliation to identify potential drug interactions
• Establish practice protocols for discussing medical marijuana/CBD before Medicare coverage expansion in 2026
• Monitor DEA Schedule III regulatory guidance and state-level prescribing requirements for cannabis products
• Review emerging research on cannabis use disorder risk factors—study notes increased premature death risk in affected patients

More on Cannabis/Marijuana